Oxurion Aims to Acquire a European CRO Valued at €3.7 Million
Oxurion has signed a letter of intent to acquire 75% of a contract research organization (CRO) operating in Europe, North Africa, and the Middle East. This transaction, valued at €3,712,500 on a 100% basis, aligns with the group's strategy to consolidate its integrated model dedicated to clinical development.
Overview of the Target Company
The target company is an independent provider involved throughout the entire clinical trial cycle, from Phase I to Phase IV. It manages multicentric projects in study management, monitoring, center surveillance, and verification of scientific and regulatory compliance. It also handles regulatory affairs, medical writing, vigilance, and real-life data programs. Since its inception, the CRO has executed over 300 projects and is projecting a turnover of around €3 million in 2025. It anticipates an average growth of 12% over the next three years, excluding group synergies, with an EBITDA for 2025 estimated at around 20%.
Financing the Acquisition
The acquisition's financing will combine cash and Oxurion shares, with management striving to maximize the use of non-dilutive instruments. The completion of the transaction remains subject to the full completion of financial, legal, and technical due diligence, initiated in March 2026 with an expected finalization by the end of May 2026. Agreement on legal documentation and, where applicable, the fulfillment of legal conditions is also necessary. Oxurion benefits from an exclusivity period until June 30, 2026, which may be extended, during which the target company and its sellers commit not to engage in discussions with third parties for a competing transaction.
Strategic Implications of the Acquisition
This acquisition is part of Oxurion's strategy to build a coherent group covering the entire continuum of clinical development. The integration would strengthen the platform by combining the multicentric operational expertise of the CRO with the data and biometrics skills of Axiodis, a subsidiary of the group. Oxurion aims to consolidate its position in a market characterized by an increased demand for partners capable of managing complex clinical projects.
